Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Cilta-cel in lenalidomide-refractory MM patients: updates from cohort A of the CARTITUDE-2 trial

Yael Cohen • 12 Jun 2022
EHA 2022
Multiple Myeloma CAR-T Ciltacabtagene autoleucel Lenalidomide
CARTITUDE-1 CARTITUDE-2 CARTITUDE-4

In this video, Yael Cohen, MD, Tel-Aviv Sourasky Medical center, Tel-Aviv, Israel, shares some updated results from a 17-month follow-up of the CARTITUDE-2 study (NCT04133636), evaluating the safety and efficacy of ciltacabtagene autoleucel (cilta-cel) in lenalidomide-refractory myeloma patients. Dr Cohen first discusses the patient cohort being evaluated, and then highlights the overall response rates (ORR) and measurable residual disease (MRD) negative responses observed. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Yael Cohen

5:54
RedirecTT-1 results: teclistamab + talquetamab in R/R multiple myeloma
Yael Cohen • 4 Jun 2023
2:37
Real-world safety and efficacy of belantamab mafodotin in R/R multiple myeloma
Yael Cohen • 27 Aug 2022
3:03
The use of single-cell RNA sequencing to identify mechanisms of drug resistance in multiple myeloma
Yael Cohen • 27 Aug 2022
2:53
Discovering drug resistance mechanisms in multiple myeloma & identifying novel treatment targets
Yael Cohen • 27 Aug 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals